CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	0	0	0.12	0.17	0.16	0.09	0.09	0.01	0.01	0.01
Cost of revenue	0	0.01	0.07	0.05	0.05	0.05	0.03	0	0	0
Gross profit	0	-0	0.05	0.12	0.11	0.04	0.06	0.01	0.01	0
Research and development	0.09	0.26	0.1	0	0	0.11	6.27	1.97	2.4	2.26
Selling, general and administrative			1.05	1.22	1.16	2.96	3.94	3.56	3.24	3.76
General and administrative	0.66	0.9	1.05
Operating expenses	0.76	1.17	1.17	1.25	1.23	3.17	10.3	5.63	5.75	6.15
Operating income	-0.76	-1.18	-1.11	-1.13	-1.11	-3.13	-10.2	-5.62	-5.74	-6.14
Interest expense	0.01	0.38	1.36	1.9	1.23	4.28	0
Interest income								0.03
Other non-operating income	-0.01	-1.48	-12.5	-7.35	-35.2	22.3	0.1	0.33	0.25	0.15
Pre-tax income		-2.66	-13.7	-8.48	-36.3	19.2	-10.1	-5.29	-5.49	-6
Income tax	0	0	0	0	0	0	0	0	0	0
Net income to minority interests									0	0
Net income	-0.77	-2.66	-13.7	-8.48	-36.3	19.2	-10.1	-5.29	-5.49	-6
EBITDA								-5.56	-5.69
EPS, basic	-562.60	-1,688.00	-1,688.00	-395.43	-62.69	7.37	-0.93
EPS, diluted	-562.60	-1,688.00	-1,688.00	-395.43	-62.69	5.61	-0.93	-3.76	-3.71	-2.52
Shares, basic (weighted)	0	0	0.01	0.02	0.58	2.61	10.9
Shares, diluted (weighted)	0	0	0.01	0.02	290	3.25	10.9	1.41	1.48	2.38

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	0.22	0.01	0.3	0.09	0.1	10.7	8.32	3.47	5.94	7.21
Receivables	0	0	0.01	0.01	0	0	0
Inventory				0	0	0.01	0.01	0.01	0	0
Other current assets						0	0.34	0.28	0.19	0.14
Total current assets	0.22	0.02	0.31	0.09	0.1	10.7	18.7	10.3	6.14	7.4
Intangible assets	0.1	0.18	0.16	0.44	0.62	0.53	0.44	0.44	0.53	0.41
Other non-current assets						0
Total assets	0.32	0.2	0.48	0.53	0.72	11.3	19.2	10.7	6.67	7.81
Accounts payable	0.07	0.24	0.33	0.32	0.35	0.76	3.27	0.32	0.27	0.27
Accrued liabilities	0	0.02	0.02	0.12	0.16	0.02	0.04	0.04	0.04	0
Total current liabilities	0.45	2.44	4.47	8.6	40.5	1.05	3.32	0.37	0.33	0.28
Total liabilities	0.48	2.44	4.47	8.6	40.5	1.05	3.32	0.37	0.33	0.28
Total debt		0.49
Paid-in capital	0.5	1.07	13.1	17.5	22.1	53.9	69.7	69.7	70.9	78.1
Retained earnings	-0.77	-3.43	-17.1	-25.6	-61.9	-43.7	-53.8	-59.1	-64.6	-70.6
Treasury stock							0	-0.27	0	-0.01
Shareholders' equity	-0.16	-2.24	-3.99	-8.07	-39.8	10.2	15.9	10.3	6.34	7.51
Minority interests									0	0.01
Total equity	-0.16	-2.24	-3.99	-8.07	-39.8	10.2	15.9	10.3	6.34	7.52
Total liabilities and equity	0.32	0.2	0.48	0.53	0.72	11.3	19.2	10.7	6.67	7.81
Shares outstanding	0	0	0.01	0.05	1.54	6.34	1.41	1.37	1.75	3.7

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-0.77	-2.66	-13.7	-8.48	-36.3	19.2	-10.1	-5.29	-5.49	-6
Depreciation and amortization								0.06	0.06
Stock-based compensation	0	0.14	0	0	0.17	0.6	0.07	0.04	0.04	0
Change in receivables	0	-0	-0	-0	-0.01	-0	0	0
Change in inventory					0	-0.01	0	0	0	0
Change in payables	0.02	0.17	0.09	-0.01	0.03	0.41	2.51	-2.95	-0.04	-0
Cash from operations	-0.45	-0.89	-1.05	-1.21	-0.43	-2.22	-7.8	-8.03	-5.3	-5.86
Acquisitions					-0.25	0
Purchases of investments							-10.1	-22.9	0
Sales and maturities of investments									6.52	0
Cash from investing	-0.01	0		0	-0.25	0	-10.1	3.45	6.32	-0.05
Stock issued	0.5	0.1	0		0	14.8	15.5	0	1.63	7.17
Share buybacks							0	-0.27	-0.17	-0.01
Cash from financing	0.68	0.68	1.34	1	0.69	12.8	15.5	-0.27	1.45	7.17
Net change in cash	0.22	-0.21	0.29	-0.22	0.01	10.6	-2.4	-4.85	2.47	1.27
Interest paid	0	0.01	0.01	0.02	0.01	0.01	0	0	0	0
Income taxes paid	0	0	0	0	0	0	0	0	0	0

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.03 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	66.9%	Gross profit / revenue.
Operating margin	-208,004.0%	Operating income / revenue.
Pre-tax margin	-201,286.0%	Pre-tax income / revenue.
Net margin	-201,355.0%	Net income / revenue.
Operating cash flow margin	-196,724.0%	Cash from operations / revenue.
Return on equity (ROE)	-69.8%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-64.4%	Net income / average total assets.
R&D / revenue	67,203.0%	Research and development expense / revenue.
SG&A / revenue	137,076.0%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	0.0%	Stock-based compensation (from the cash flow statement) / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-45.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-59.2%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-48.4%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-42.3%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-60.1%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-49.3%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	18.5%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-22.0%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y	17.1%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-25.9%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	61.2%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	61.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-39.8%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-61.7%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	12.9x	Current assets / current liabilities.
Quick ratio	12.5x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	12.5x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	7.4%	Total liabilities / total assets.
Working capital	$8.3M	Current assets - current liabilities.
Goodwill and intangibles / assets	3.8%	(Goodwill + intangible assets) / total assets.
Tangible book value	$8.3M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.00x	Revenue / average total assets.
Inventory turnover	0.01x	Cost of revenue / average inventory.
Days inventory	45,900 days	365 x average inventory / cost of revenue.
Days payables	251,314 days	365 x average accounts payable / cost of revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.63	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$0.00	Revenue / diluted weighted shares.
Operating cash flow per share	-$1.59	Cash from operations / diluted weighted shares.
Book value per share	$1.33	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$1.28	Tangible book value / shares outstanding.
Cash per share	$1.34	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$6.8M	Share price x shares outstanding.
Enterprise value	-$1.9M	Market cap + total debt - cash - short-term investments.
P/S	2,263x	Market cap / revenue.
P/B	0.78x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	0.82x	Market cap / tangible book value, when positive.
Earnings yield	-89.0%	Net income / market cap (the inverse of P/E).
Shareholder yield	0.0%	(Dividends paid + share buybacks) / market cap.

What was CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s revenue in fiscal 2025?

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. reported revenue of $6.0K for fiscal 2025, 45.5% lower than the year before.

Was CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. profitable in fiscal 2025?

No. It reported a net loss of $6.0M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.